Transcriptomics

Dataset Information

0

Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction


ABSTRACT: Two molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) have been proposed: the “Classical” and “Basal-like” subtypes. However, the “molecular” classification has not been applied in real-world clinical practice. This study aimed to establish patient-derived organoids (PDOs) for PDAC and evaluate their application in subtype classification and clinical outcome prediction. We constructed a PDO library for morphologic and RNA-seq analyses and drug response assays in vitro. PDOs of PDAC were established at a high efficiency (> 70%) with at least 100,000 live cells. Morphologically, PDOs were classified as gland-like structures (GL type) or densely proliferating inside (DP type). RNA-seq analysis revealed that the “morphological” subtype (GL vs. DP) roughly corresponded to the “molecular” subtype (“Classical” vs. “Basal-like”). The proposed “morphological” classification predicted clinical treatment response and prognosis; the median overall survival of patients with GL type were significantly longer than that of those with DP type (P < 0.005). The GL type showed a better response to gemcitabine than the DP type in vitro, whereas the drug response of the DP type was improved by the combination of ERK and autophagy inhibition. PDAC PDOs facilitated subtype determination and clinical outcome prediction, thereby advancing precision medicine for PDAC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE228801 | GEO | 2024/04/11

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-01-14 | GSE138452 | GEO
2021-01-14 | GSE138451 | GEO
2021-01-14 | GSE144750 | GEO
2021-01-14 | GSE138142 | GEO
2021-01-14 | GSE138144 | GEO
2021-01-14 | GSE138143 | GEO
2021-08-07 | GSE181593 | GEO
2024-04-02 | MTBLS9418 | MetaboLights
2022-03-04 | ST002113 | MetabolomicsWorkbench
2024-02-05 | GSE234737 | GEO